Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

by Kojima, Akihito , Kawakami, Hisato , Ryu, Min-Hee , Shitara, Kohei , Sakai, Daisuke , Kawaguchi, Yoshinori , Saito, Kaku , Sugihara, Masahiro , Iwasa, Satoru , Yamaguchi, Kensei , Chung, Hyun-Cheol , Lee, Jeeyun , Sugimoto, Naotoshi , Yabusaki, Hiroshi , Kamio, Takahiro , Bang, Yung-Jue

in Adenocarcinoma / Adenocarcinoma - drug therapy / Adult / Aged / Aged, 80 and over / Antibodies / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Body weight / Bone Marrow - drug effects / Breast cancer / Camptothecin - adverse effects / Camptothecin - analogs & derivatives / Camptothecin - therapeutic use / Chemotherapy / Cytotoxicity / DNA topoisomerase / Drug dosages / Epidermal growth factor / ErbB-2 protein / Esophageal Neoplasms - drug therapy / Female / Gastric cancer / Growth factors / Humans / Hybridization / Immunoconjugates - adverse effects / Immunoconjugates - therapeutic use / Immunotherapy / Irinotecan / Irinotecan - therapeutic use / Lung cancer / Lung diseases / Lung Diseases, Interstitial - chemically induced / Male / Metastasis / Middle Aged / Monoclonal antibodies / Myelosuppression / Paclitaxel / Paclitaxel - therapeutic use / Pneumonitis / Receptor, ErbB-2 - analysis / Stomach Neoplasms - drug therapy / Survival Analysis / Targeted cancer therapy / Trastuzumab / Tumors

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

2020

Confirm

Do you wish to request the book?

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kojima, Akihito,

Kawakami, Hisato,

Ryu, Min-Hee,

Shitara, Kohei,

Sakai, Daisuke,

Kawaguchi, Yoshinori,

Saito, Kaku,

Sugihara, Masahiro,

Iwasa, Satoru,

Yamaguchi, Kensei,

Chung, Hyun-Cheol,

Lee, Jeeyun,

Sugimoto, Naotoshi,

Yabusaki, Hiroshi,

Kamio, Takahiro,

Bang, Yung-Jue

2020

Overview

Approximately 15 to 20% of gastric adenocarcinomas express HER2. Trastuzumab deruxtecan is an antibody-drug conjugate composed of trastuzumab and the topoisomerase I inhibitor deruxtecan. In a randomized trial, the antibody-drug conjugate led to higher response and longer overall survival than physician’s choice of therapy among patients with relapsed disease.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adenocarcinoma

/ Adenocarcinoma - drug therapy

/ Adult

/ Aged

/ Aged, 80 and over

/ Antibodies

/ Antibodies, Monoclonal, Humanized - adverse effects